|
Benefits
of REBETRON Combination Therapy
In
previously untreated patients:
In
clinical trials with REBETRON Combination Therapy, 40% of patients
who were treated with 48 weeks of REBETRON Combination Therapy
had undetectable virus levels as compared to 15% of patients who
were treated with 48 weeks of INTRON® A alone.
In
patients treated with interferon who have relapsed:
Before
being approved by the Food and Drug Administration (FDA), the
safety and effectiveness of REBETRON Combination Therapy were
evaluated in two clinical trials. Participating in the trials
were chronic hepatitis C patients who had received treatment with
INTRON® A but relapsed after having an initial response to the
therapy. In almost half of these patients, 6 months of REBETRON
Combination Therapy resulted in a loss of detectable hepatitis
C virus as well as improvement in the condition of the liver,
representing a significant improvement compared with interferon
treatment alone.
Ninety-four
percent of the relapsed chronic hepatitis C patients who took
part in clinical trials for REBETRON Combination Therapy completed
their course of therapy.
Choose a topic
below:
|
